Literature DB >> 29082588

Determinants of physical, affective, and cognitive fatigue during breast cancer therapy and 12 months follow-up.

Martina E Schmidt1, Joachim Wiskemann2, Andreas Schneeweiss3, Karin Potthoff2,4, Cornelia M Ulrich5, Karen Steindorf1.   

Abstract

Fatigue is common in cancer survivors but often insufficiently treated. Due to its complexity a one-size-fits-all treatment seems not appropriate. To gain more information on influencing factors and sub-dimensions of fatigue we investigated potential determinants and correlates of physical, affective, and cognitive fatigue in breast cancer survivors during and after adjuvant therapy. Within the follow-up of two randomized controlled trials physical, affective, and cognitive fatigue were repeatedly assessed during and up to 12 months after cancer therapy with the 20-item Fatigue Assessment Questionnaire in 255 breast cancer survivors. Determinants of the different fatigue dimensions over time were explored with linear mixed models. Chemotherapy appeared as significant precipitating factor for physical fatigue. However, type of cancer therapy had no impact on fatigue one year post-treatment. Obesity was significantly associated with increased physical fatigue throughout all time points (Δ=15.5 at 12 months) whereas exercise appeared to be beneficial (Δ = -6.3). In contrast, affective fatigue was significantly associated with poor social support and worries about the future. In addition, poor sleep quality and previous use of psychopharmaceuticals were significantly associated with physical, affective, as well as cognitive fatigue. Further, hot flashes were associated with increased physical and cognitive fatigue. In conclusion, the broad diagnosis 'fatigue' in cancer survivors needs to be recognized as a diversity of symptoms determined by specific characteristics and likely different etiologies. Taking potential influencing factors such as obesity, physical inactivity, sleep problems, hot flashes, lack of social support, or psychological disorders into consideration might enable a better, individually-tailored fatigue treatment.
© 2017 UICC.

Entities:  

Keywords:  breast cancer; characteristics; determinants; mental fatigue; physical fatigue

Mesh:

Substances:

Year:  2017        PMID: 29082588     DOI: 10.1002/ijc.31138

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Pain mapping and characteristics in breast cancer survivors during task-oriented training: analysis at 3, 6, and 9 months.

Authors:  Bruna Baungarten Hugen Back; Kamilla Zomkowski; Mariana Dos Santos Hermes; Natália de Souza Cunha; Anke Bergmann; Fabiana Flores Sperandio
Journal:  Support Care Cancer       Date:  2021-01-07       Impact factor: 3.603

2.  Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis.

Authors:  Martina E Schmidt; Joachim Wiskemann; Karen Steindorf
Journal:  Qual Life Res       Date:  2018-05-08       Impact factor: 4.147

3.  L-Thyroxine intake as a potential risk factor for the development of fatigue in breast cancer patients undergoing chemotherapy.

Authors:  Martina E Schmidt; Joachim Wiskemann; Theron Johnson; Nina Habermann; Andreas Schneeweiss; Karen Steindorf
Journal:  Support Care Cancer       Date:  2018-02-14       Impact factor: 3.603

4.  Subgroups of patients undergoing chemotherapy with distinct cognitive fatigue and evening physical fatigue profiles.

Authors:  Lisa Morse; Kord M Kober; Carol Viele; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Jon D Levine; Christine Miaskowski
Journal:  Support Care Cancer       Date:  2021-07-04       Impact factor: 3.603

5.  The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote.

Authors:  Jennifer Y Sheng; Cesar A Santa-Maria; Amanda L Blackford; David Lim; Ashley Carpenter; Karen L Smith; Gary I Cohen; Janelle Coughlin; Lawrence J Appel; Vered Stearns; Claire Snyder
Journal:  J Cancer Surviv       Date:  2021-05-20       Impact factor: 4.062

6.  Obese Breast Cancer Patients and Survivors: Management Considerations.

Authors:  Jennifer Y Sheng; Dipali Sharma; Gerald Jerome; Cesar Augusto Santa-Maria
Journal:  Oncology (Williston Park)       Date:  2018-08-15       Impact factor: 2.533

Review 7.  Sleep and gynecological cancer outcomes: opportunities to improve quality of life and survival.

Authors:  Caroline Zhao; Allison Grubbs; Emma L Barber
Journal:  Int J Gynecol Cancer       Date:  2022-05-03       Impact factor: 4.661

8.  High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship.

Authors:  Sara Mijwel; Anna Jervaeus; Kate A Bolam; Jessica Norrbom; Jonas Bergh; Helene Rundqvist; Yvonne Wengström
Journal:  J Cancer Surviv       Date:  2019-03-25       Impact factor: 4.442

9.  Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.

Authors:  Jonna K VAN Vulpen; Maike G Sweegers; Petra H M Peeters; Kerry S Courneya; Robert U Newton; Neil K Aaronson; Paul B Jacobsen; Daniel A Galvão; Mai J Chinapaw; Karen Steindorf; Melinda L Irwin; Martijn M Stuiver; Sandi Hayes; Kathleen A Griffith; Ilse Mesters; Hans Knoop; Martine M Goedendorp; Nanette Mutrie; Amanda J Daley; Alex McConnachie; Martin Bohus; Lene Thorsen; Karl-Heinz Schulz; Camille E Short; Erica L James; Ronald C Plotnikoff; Martina E Schmidt; Cornelia M Ulrich; Marc VAN Beurden; Hester S Oldenburg; Gabe S Sonke; Wim H VAN Harten; Kathryn H Schmitz; Kerri M Winters-Stone; Miranda J Velthuis; Dennis R Taaffe; Willem VAN Mechelen; Marie José Kersten; Frans Nollet; Jennifer Wenzel; Joachim Wiskemann; Irma M Verdonck-DE Leeuw; Johannes Brug; Anne M May; Laurien M Buffart
Journal:  Med Sci Sports Exerc       Date:  2020-02

10.  Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma.

Authors:  Russell F Palm; Heather S L Jim; David Boulware; Peter A S Johnstone; Arash O Naghavi
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.